Novo, Lilly Weight-Loss Drug Juggernaut Has Nowhere to Go But Up

Novo, Lilly Weight-Loss Drug Juggernaut Has Nowhere to Go But Up

Source: 
BioSpace
snippet: 

In the pharma industry, there are blockbuster drugs and—for the truly fortunate companies—mega blockbusters. However, Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro are in a category all to themselves, which is confounding analysts trying to get a handle on their potential market size amid the frenzied demand for these weight-loss medicines.